scholarly journals Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines.

1991 ◽  
Vol 266 (25) ◽  
pp. 16755-16763
Author(s):  
M. Nistér ◽  
L. Claesson-Welsh ◽  
A. Eriksson ◽  
C.H. Heldin ◽  
B. Westermark
Keyword(s):  
Growth Factor ◽  
Malignant Glioma ◽  
Differential Expression ◽  
Cell Lines ◽  
Glioma Cell ◽  
Growth Factor Receptors ◽  
Platelet Derived Growth Factor ◽  
Glioma Cell Lines ◽  
Human Malignant Glioma

Response of malignant glioma cell lines to epidermal growth factor and platelet-derived growth factor in a serum-free medium

1990 ◽  
Vol 73 (1) ◽  
pp. 106-112 ◽  
Author(s):  
Ian F. Pollack ◽  
Margaret S. Randall ◽  
Matthew P. Kristofik ◽  
Robert H. Kelly ◽  
Robert G. Selker ◽  
...  
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Malignant Glioma ◽  
Cell Lines ◽  
Glioma Cell ◽  
Platelet Derived Growth Factor ◽  
Glial Tumors ◽  
Serum Free ◽  
Glioma Cell Lines ◽  
Epidermal Growth

✓ The use of a serum-free culture system for assessing the growth factor responsiveness of malignant glial cells is described. The mitogenic properties of epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) were examined in three human malignant glioma cell lines (T98G, U87, and U138). Each of the three had high-affinity EGF receptors and all responded in a dose-dependent fashion to physiological concentrations of EGF. These cell lines also showed a pronounced mitogenic response to PDGF which equaled or exceeded that achieved with EGF. Simultaneous stimulation with both factors produced an additive response, which approximated that obtained in medium supplemented with 10% fetal calf serum. The authors conclude that functional EGF and PDGF receptors were present in the human malignant glial tumors studied. The response of the human glioma lines to these growth factors in many respects parallels the response seen in fetal astrocytes tested under similar conditions. In contrast, the behavior of two chemically induced rat gliomas (9L and C6) differed significantly from that seen in the human lines, suggesting that the rat lines may not be entirely acceptable as models for studying the growth characteristics of human malignant glial tumors.

Human Malignant Glioma Cell Lines are Refractory to Retinoic Acid-Mediated Differentiation and Sensitization to Apoptosis1

2000 ◽  
Vol 10 (3) ◽  
pp. 159-168 ◽  
Author(s):  
Friederike Schmidt ◽  
Peter Groscurth ◽  
Johannes Dichgans ◽  
Michael Weller
Keyword(s):  
Retinoic Acid ◽  
Malignant Glioma ◽  
Cell Lines ◽  
Glioma Cell ◽  
Glioma Cell Lines ◽  
Human Malignant Glioma

scholarly journals Antiproliferative Effect of Multiple Autocrine Loop Blockade in Human Malignant Glioma Cell Lines

1995 ◽  
Vol 35 (10) ◽  
pp. 723-727 ◽  
Author(s):  
Masanori KURIMOTO ◽  
Kanehito NOGAMI ◽  
Tsuneaki OGIICHI ◽  
Michiharu NISHIJIMA ◽  
Akira TAKAKU
Keyword(s):  
Malignant Glioma ◽  
Cell Lines ◽  
Glioma Cell ◽  
Antiproliferative Effect ◽  
Autocrine Loop ◽  
Glioma Cell Lines ◽  
Human Malignant Glioma

Antiproliferative effect of trapidil, a platelet-derived growth factor antagonist, on a glioma cell line in vitro

1990 ◽  
Vol 73 (3) ◽  
pp. 436-440 ◽  
Author(s):  
Jun-ichi Kuratsu ◽  
Yukitaka Ushio
Keyword(s):  
Growth Factor ◽  
Cell Lines ◽  
Glioma Cell ◽  
Glioma Cells ◽  
Inhibitory Effect ◽  
Platelet Derived Growth Factor ◽  
Content Type ◽  
Glioma Cell Lines ◽  
Fine Print

✓ Platelet-derived growth factor (PDGF) is produced by glioma cells. However, there is heterogeneity among glioma cell lines in the production of PDGF. It has been demonstrated that U251MG cells produce a PDGF-like molecule while U105MG cells do not. Trapidil, a specific antagonist of PDGF, competes for receptor binding with PDGF. Therefore, the inhibitory effect of trapidil on the proliferation of glioma cells was investigated in vitro using two glioma cell lines. At 100 µg/ml, trapidil significantly inhibited the proliferation of U251MG cells (which produce the PDGF-like molecule). At the same trapidil concentration, the proliferation of U105MG cells (which do not produce the PDGF-like molecule) was not inhibited. The inhibitory effect of trapidil was remarkable on Days 3 and 4 of culture. After 4 days of incubation, the proliferation of U251MG cells was 46% of the control preparation. Trapidil enhanced the antitumor effect of 3-((4-amino-2-methyl-5-pyrimidinyl)ethyl)-1-(2-chloroethyl)-1-nitro-sourea (ACNU) against U251MG cells. The enhancing effect was highest on Days 4 and 6 of culture. After 6 days of incubation in the presence of 100 µg/ml trapidil and 1 µg/ml ACNU, the proliferation of U251MG cells was 18% of the control preparation. These findings suggest that trapidil interrupts the autocrine loop at the PDGF and PDGF-receptor level and that combination therapy with trapidil and ACNU may be useful in the treatment of glioma.

Apoptotic induction by BE16627B on human malignant glioma cell lines by an anti-matrix metalloproteinase agent

2003 ◽  
Vol 20 (1) ◽  
pp. 13-19 ◽  
Author(s):  
Daizo Yoshida ◽  
Kunihiro Watanabe ◽  
Hiroshi Takahashi ◽  
Yuichi Sugisaki ◽  
Akira Teramoto
Keyword(s):  
Matrix Metalloproteinase ◽  
Malignant Glioma ◽  
Cell Lines ◽  
Glioma Cell ◽  
Glioma Cell Lines ◽  
Human Malignant Glioma ◽  
Apoptotic Induction
Sign in / Sign up

Export Citation Format

Share Document